See your blood in a new light.

VidaLens is a reagent-free, software-defined optical platform for blood diagnostics, surfacing more from a single sample than conventional tests ever could.

See how it works

A ribbon model of haemoglobin: four teal protein chains coiled around each other, each holding a red heme group.

The problem

Standard blood work is fifty-year-old technology.

The complete blood count counts. It does not describe. Clinicians work from averages and chemical proxies, and order a second test when the first one is ambiguous.

The complete blood count has worked essentially the same way for about fifty years. It reports how many, as averages and chemical proxies, and it does not describe what the cells themselves look like or how they behave. When the answer comes back ambiguous, the usual next step is to order a second test.

50+

Years the underlying CBC method has gone essentially unchanged.

$70B

Global hematology market.

~30%

Of complete blood counts trigger a follow-on test.

What it does

Light reads what chemistry misses.

One optical reading, interpreted by software, surfaces signal that standard panels discard. Designed and tested for reliable performance across populations.

VidaLens takes one optical reading of a blood sample and interprets it in software. Nothing is added to the sample and nothing is consumed. From that single capture the platform is designed to describe individual cells rather than only count them, and to report back in the metrics a clinician already works from.

A cluster of red blood cells, each a rounded disc dimpled in the centre, turning slowly.

01 Structure

Cell-level detail

Captures the structure of individual cells rather than reducing a population to counts.

The backbone of a haemoglobin tetramer, four coiled chains, shifting between its two resting shapes as it turns.

02 Composition

Deeper composition

Surfaces compositional and functional signal that chemistry alone does not reach.

03 Interpretation

Familiar results

Software translates the reading into the metrics a clinician already works from.

Learn the details

The same field, twice

The same cells, measured two ways.

A brightfield frame and its measured optical-path map are the same field of view. Scroll, and the photograph rises into the surface it always encoded.

A measured optical-path surface of a single field of red blood cells, rendered as a teal relief map in which each cell rises as a rounded dome above a flat plate. — Measured optical path, red cells in a single field. Vertical exaggeration ×15. Scale bar 10 µm. Scale derived from the capture optics: a 20× objective with a 2.4 µm sensor pixel pitch gives 0.120 µm per pixel at the sample plane.

Roadmap

Where the platform goes.

Five phases from prototype to expanded claims.

0 Prototype and Q-Sub
1 Research-use label
2 510(k) submission
3 Clearance and first installs
4 Expanded claims

Phase 0 now to month 6

Prototype and Q-Sub

Building against real samples and opening the regulatory conversation early. Alpha partner: Wake Forest Baptist Hospital.

Phase 1 month 6 to 12

Research-use label

Placements with pharma and academic groups; independent publication.

Phase 2 month 12 to 18

510(k) submission

Validation sites run the instrument against established methods.

Phase 3 month 18 to 24

Clearance and first installs

Early adopters, first revenue.

Phase 4 month 24 to 36

Expanded claims

Labs and urgent care.

Pathway modelled on the Sysmex XW-100 precedent.

Partner with us.

Run a pilot, shape the science.

Pilots, research access and investment. The same platform, three different conversations.

Hospitals and health systems

Pilot in emergency and intensive care settings with real samples, and get early access to new capability as it ships.

Research laboratories

Access optical cell data for publication and pre-clinical work.

Strategic investors

We are currently raising.

Questions

Questions people ask first.

The four an unfamiliar reader asks before anything else. Four more are answered on the technology page.

What is VidaLens?

VidaLens is a pre-revenue medical technology company developing a label-free, reagent-free optical platform for blood diagnostics. The platform is designed to take a single optical reading of a blood sample and interpret that reading in software. VidaLens is at prototype stage and is not cleared by FDA.

Is VidaLens FDA cleared?

No. Neither device is cleared by FDA, neither is for sale, and neither is for use in diagnostic procedures. The regulatory pathway is publicly described as modelled on the Sysmex XW-100 dual 510(k) and CLIA Waiver precedent.

Does the platform use reagents?

No. The optical core is designed to read the sample directly, so nothing is added to the sample and nothing is consumed per reading. That is a description of the measurement method and of the intended design, not a statement about what the platform finds.

Who is the platform for today?

Investors, research groups and prospective hospital partners. VidaLens is at prototype stage, so there is no patient-facing product and no clinical availability. This site is written for people evaluating the technology, not for people seeking a test.

Next step

Let's talk.

We will connect you with the right person for demos, pilots and investment conversations.

General enquiries: [email protected]
Partnerships, pilots and investment: [email protected]